Amphastar Pharmaceuticals, Inc. (AMPH)
NASDAQ: AMPH · Real-Time Price · USD
18.72
-0.15 (-0.79%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Amphastar Pharmaceuticals Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 720.53 | 719.89 | 731.97 | 644.4 | 498.99 | 437.77 |
Revenue Growth | -1.39% | -1.65% | 13.59% | 29.14% | 13.98% | 25.13% |
Gross Profit Gross Profit Growth | 341.13 | 356.06 | 373.86 | 351.12 | 248.86 | 199.74 |
Operating Income Operating Income Growth | 116.74 | 140.4 | 205.42 | 196.99 | 107.5 | 69.89 |
Net Income Net Income Growth | 79.23 | 98.09 | 159.52 | 137.55 | 91.39 | 64.49 |
Earnings Per Share EPS Growth | 1.66 | 2.03 | 3.06 | 2.60 | 1.74 | 1.25 |
EPS Growth | -39.86% | -33.66% | 17.69% | 49.43% | 39.20% | 4066.67% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
United States United States Growth | 677.87 | 681.42 | 707.68 | 635.19 | 486.83 | 419.87 |
China China Growth | 5.59 | 3.18 | 4.34 | 4.51 | 4.7 | 6.02 |
France France Growth | 37.07 | 35.28 | 19.95 | 4.7 | 7.46 | 11.88 |
Total Total Growth | 720.53 | 719.89 | 731.97 | 644.4 | 498.99 | 437.77 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 294.15 | 285.01 | 223.85 | 259.01 | 177.96 | 138.87 |
Total Debt Total Debt Growth | 686.38 | 656 | 0 | 623.64 | 102.58 | 104.66 |
Net Cash (Debt) Net Cash Growth | -392.23 | -370.99 | 223.85 | -364.64 | 75.38 | 34.21 |
Net Cash Growth | - | - | - | - | 120.34% | -15.63% |
Net Cash Per Share Net Cash Per Share Growth | -8.28 | -7.69 | 4.30 | -6.88 | 1.44 | 0.69 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 168.88 | 156.12 | 213.39 | 183.5 | 89.18 | 97.99 |
Capital Expenditures CapEx Growth | -33.69 | -34.88 | -41.04 | -38.17 | -24.03 | -27.46 |
Free Cash Flow Free Cash Flow Growth | 135.19 | 121.23 | 172.35 | 145.34 | 65.15 | 70.54 |
Free Cash Flow Growth | -10.01% | -29.66% | 18.58% | 123.09% | -7.64% | 201.30% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 47.34% | 49.46% | 51.08% | 54.49% | 49.87% | 45.63% |
Operating Margin | 16.20% | 19.50% | 28.06% | 30.57% | 21.54% | 15.96% |
Pretax Margin | 14.27% | 17.17% | 25.93% | 26.59% | 23.26% | 19.22% |
Profit Margin | 11.00% | 13.63% | 21.87% | 21.65% | 18.55% | 14.51% |
FCF Margin | 18.76% | 16.84% | 23.55% | 22.55% | 13.06% | 16.11% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 11.23 | 13.19 | 12.13 | 23.79 | 16.10 | 18.63 |
Forward PE | 6.76 | 7.78 | 9.42 | 20.77 | 16.29 | 16.96 |
P/FCF Ratio | 6.11 | 10.08 | 10.26 | 20.46 | 20.69 | 15.75 |
PS Ratio | 1.15 | 1.70 | 2.42 | 4.61 | 2.70 | 2.54 |